samedan logo
 
 
spacer
home > events calendar > more about event
PHARMACEUTICAL INDUSTRY EVENTS CALENDAR

3D Cell Culture 2018

SMi - 3D Cell Culture 2018

21-22 February 2018
Holiday Inn Kensington Forum, London UK

Building on the sell-out success of the launch event, SMi Group is delighted to announce the return of 3D Cell Culture, taking place on 21st and 22nd of February 2018, in London UK.

3D Cell Culture is rapidly growing with incredible potential for industrial application and a widespread reach that can be seen across many different fields, such as 3D bioprinting and microfluidics.

The 2nd annual conference will explore these overlapping areas and will combine pioneering breakthroughs with scientific research to strengthen your commercial success. Join us for exclusive insight into key topics such as disease models, organoids, organ-on-a-chip technologies, iPSC advances plus much more!

FEATURED SPEAKERS:

·        Gary Allenby, Business Development Director and Chief Scientific Officer, Aurelia Bioscience

·        Mr Stefan Przyborski, Scientific Founder, ReInnervate Limited

·        Mr Ricardo Baptista, Lead Scientist Process Development, Cell and Gene Therapy Catapult

·        Dr Nicholas Leslie, Tumour Biologist, Heriot-Watt University

·        Dr Suwan Jaysinghe, Professor of Bioengineering, University College London

·        Dr Max Salick, Postdoctoral Researcher, Novartis Institutes for Biomedical Research

·        Dr Patrick Kugelmeier, Director of Science, Kugelmeiers

·        Dr Vitor Santo, Senior Scientist, Immunocore

·        Mr Christopher Schofield, Investigator, GSK

·        Mr David Pan, Programme Manager (Regenerative Medicine), UK Regenerative Medicine Platform

·        Dr Reyk Horland,Head of Business Development, TissUse GmbH


REASONS TO ATTEND IN 2018

·        Uncover the biology of human neurodevelopment diseases in 3D by merging cutting edge technologies in CRISPR editing and single cell sequencing

·        Take a 3D biology approach to overcome challenges for well based screening with exclusive insight into electrospun micro-scaffold based biology

·        Develop strategies for optimising placement of cells in printing by identifying key developments in the overlap of 3D bioprinting and 3D cell culturing

·        Discover new approaches to predictive substance testing through innovative case study insight into multi-organ-chip technology

·        Benefit from an agenda tailored towards driving clinical development through ground breaking case studies on the Zika virus and tuberous sclerosis


2017 ATTENDEE TESTIMONIALS

“Very good presentations and a few outstanding ones... I made some useful contacts” ASTERAND BIOSCIENCE

“The conference was wonderfully organised” NOVARTIS

“Good start, love to see the event occur again” THERMO FISHER SCIENTIFIC

For further details visit www.3D-cellculture.com/samedan or contact the team on +44 (0)20 7827 6000

 

phone +44 (0)20 7827 6000
email events@smi-online.co.uk
web www.3D-cellculture.com/samedan
email Holiday Inn Kensington Forum, London UK
 
Print this page
Send to a friend
   
spacer
Industry Events

Clinical Trial Supply Forum 2018

22-24 January 2018, London, UK

In the constantly changing environment of Clinical Trial Supply, cost efficiency, end to end visibility, logistics and managing complex pipelines are STILL crucial elements that need addressing!
More info >>

Banner of DIA_events_95 on Samedan

Banner of OCT_East_Asia_events_102 on Samedan
White Papers

Clinical Trials in Ukraine: Orange Paper Overview and 1st Half Year 2014

Synergy Research Group

The Orange Paper is an analytical report about the clinical trials market in Russia, published quarterly by the contract research organization Synergy Research Group. The first edition of Orange Paper was released in 2006, and at the moment 31 issues have already published. Now, thanks to Synergy Group Ukraine, obtaining information about the market of clinical trials in Ukraine has become possible. In Ukraine, during the period from 1996 to 2013, applicants had obtained 3,864 positive conclusions about the possibility of conducting clinical trials of drugs, both for domestic and foreign manufacturers, including conduct of multinational multi-center clinical trials (hereinafter – MMCTs)
More info >>


News and Press Releases

New research calls for pathology services to be better funded and prioritised


More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement